EKF
German site
  • Home
  • Produkte
  • Über uns
  • Aktuelles
  • Support
  • Investor relations
  • Kontakt
  • Diabetes
  • Anämie
  • Laktat
  • Organschädigung

 

 

Willkommen bei EKF Diagnostics

Die EKF Diagnostics Gruppe ist ein weltweit tätiger Hersteller von Point-of-care Geräten zur Messung von Glukose, Laktat, Hämoglobin, Hämatokrit und Glykohämoglobin (HbA1c). 

Unsere Blutanalysegeräte sind einfach zu bedienen und wurden entwickelt um schnelle und präzise Ergebnisse zur Diagnose von Anämie, Diabetes und ähnlichen Erkrankungen zu liefern.

EKF Analysegeräte werden in mehr als 70 Ländern von Gesundheitsfachkräften in Blutspendediensten, Arztpraxen, Krankenhäusern, Laboratorien und der Sportmedizin verwendet.

Wir sind außerdem weltweit führend bei der Herstellung und Distribution von Biomarkern speziell für akute Verletzungen der Nieren, Leber und der Bauchspeicheldrüse.

Unsere Microtiterplatten Assay Kits werden insbesondere für Untersuchungen zur Sicherheit und Wirksamkeit von Kandidaten für neue Arzneimittel in klinischen Studien eingesetzt. 

 

Legal Statement: This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. EKF Diagnostics Holdings plc does not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration, or usage in the country of your origin.

  • Aktuelles
  • Investor relations
25 April 2012. Stanbio Laboratory to Transition HemoPoint® H2 Hemoglobin System to Alere Inc Stanbio Laboratory announced today that the sales, marketing and service functions in the United States for its popular point-of-care HemoPoint® H2 hemoglobin system has been transitioned to Alere, Inc.
25 April 2012. The majority of NHS spending on diabetes is avoidable The majority of NHS spending on diabetes is avoidable, says a report in the journal Diabetic Medicine
29 March 2012. Argutus Medical Ltd applies for ISO 13485 Certification Argutus Medical, a subsidiary of EKF Diagnostics Holdings plc, is delighted to announce that they have applied for an ISO 13485 certification
20 March 2012. Appointment of Group Head of Sales EKF Diagnostics Holdings plc, the growing in-vitro diagnostics company, announces that Tony Wilks has joined the Company as Group Head of Sales. The appointment is not a main Board appointment.
19 March 2012. ß-Hydroxybutyrate LiquiColor® Kit now available for Beckman Synchron® Analysers Stanbio Laboratory is announcing the availability of a new β-Hydroxybutyrate LiquiColor® kit for the Beckman Coulter Synchron® CX / LX / DX clinical systems.

Twitter Facebook Linkedin
RSS RSS
Update on the Disposal of International Brand Licensing AG Update on the Disposal of International Brand Licensing AG
4 April 2012. Notification of major interest in shares Notification of major interest in shares
27 March 2012. Disposal of International Brand Licensing AG EKF Diagnostics Holdings plc, the growing in-vitro diagnostics company, announces that it has sold its Swiss subsidiary, International Brand Licensing AG for a cash consideration of £50,000, payable over a 2 year period.
21 March 2012. Final results for the year ended 31 December 2011 EKF Diagnostics Holdings plc, the growing in-vitro diagnostics company, announces its audited final results for the year ended 31 December 2011, a year of continued progress.
16 March 2012 Trading Update & Notice of Final Results EKF to announce final results on 21 March 2012.

Twitter Facebook Linkedin
RSS RSS

LINKS

Hemoglobin Analysis HbA1c DeterminationGlucose TestingLactate MeasurementBiomarker Detection

Produkte

prod01
Hemo Control
prod01
Quo-Test
prod01
Biosen
prod01
Lactate Scout
prod01
Biomarkers
  • AGB
  • Datenschutz
  • Impressum
  • Site Map
  • Remote Support
  • Allgemeine Verkaufs- und Lieferbedingungen
Website designed by atticusdigital